Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068752 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
A Phase 2 study of Pancreas Cancer, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05068752: Active Phase 2 study of Pancreas Cancer, sponsored by HonorHealth Research Institute.
NCT05068752 is a Phase 2 study of Pancreas Cancer that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 12 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05068752, a Phase 2 study of Pancreas Cancer, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
Primary Outcome
Disease control rate (DCR) is defined as the combination of patients with complete response + partial response + stable disease at 16 weeks, divided by the total number of patients. Response is defined using RECIST v1.1 imaging criteria.
Conditions Studied
Interventions
- DRUG Vemurafenib
- DRUG Sorafenib
Study Locations (1)
Arizona
- HonorHealth Research Institute - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 2 |
What the registry record for NCT05068752 still lists
NCT05068752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vemurafenib is the first listed.
NCT05068752 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05068752 about?
NCT05068752 is a clinical study titled "Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer". The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
What is the current status of trial NCT05068752?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-10-28. Estimated completion is 2024-12-30.
What conditions does trial NCT05068752 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT05068752?
The interventions under investigation include: Vemurafenib (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT05068752?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05068752 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05068752's enrollment target sits among peer trials
12 55th of 54 the lowest of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI